SOURCE: Chiesi USA, Inc.

Chiesi USA, Inc.

June 22, 2016 08:00 ET

Chiesi Completes the Acquisition of Three Hospital Products -- Kengreal®, Cleviprex® and Argatroban™ for Injection

PARMA, ITALY--(Marketwired - June 22, 2016) - Chiesi USA, Inc. and Chiesi Farmaceutici S.p.A., Chiesi USA's parent company, announced today that the companies have finalized the acquisition of multinational rights to Kengreal® (cangrelor) for injection and Cleviprex® (clevidipine) injectable emulsion, as well as rights to Argatroban™ for Injection, 50 mg per 50 mL from The Medicines Company. All three products are for use in the hospital setting and approved for sale in the U.S. The Medicines Company is receiving approximately $262 million in cash at closing, and is entitled to receive up to $480 million in sales-based milestone and royalty payment obligations.

"Kengreal and Cleviprex significantly expand our hospital portfolio in the United States, and this is why we chose to target them," said Ugo Di Francesco, CEO of Chiesi Farmaceutici S.p.A., Chiesi USA's parent company. "Acquiring these products fits with our global strategy of reinvesting in our businesses to help patients and to grow our company."

"Chiesi USA continues to be a primary focus for investment," Di Francesco added. "Our team is actively working to identify and evaluate other acquisition opportunities and we intend to continue to expand our business in the United States."

Ken McBean, President and Chief Executive Officer of Chiesi USA, said, "Our acquisition of these products further strenghtens our position as a leader in the hospital and adjacent specialty product space. We are excited to be able to offer these products to healthcare providers to enhance care for their patients who can benefit from these medications."

Chiesi Farmaceutici

Headquartered in Parma, Italy Chiesi Farmaceutici is an international research-focused Healthcare group, with over 80 years of experience in the pharmaceutical industry. Chiesi researches, develops and markets innovative drugs in the respiratory therapeutics, specialist medicine and rare diseases areas. Its R&D centers in Parma (Italy), Paris (France), Cary (USA), Chippenham (UK) and the R&D team of the acquired Danish company Zymenex, integrate their efforts to advance Chiesi's pre-clinical, clinical and registration programs. Chiesi employs over 4,500 people, 560 of whom are solely dedicated to Research and Development activities.

For more information, please visit the website

Chiesi USA, Inc.

Chiesi USA, Inc., headquartered in Cary, N.C., is a specialty pharmaceutical company focused on commercializing products for the hospital and adjacent specialty markets. Key elements of the Company's strategy are to focus its commercial and development efforts in the hospital and adjacent specialty product sector within the U.S. pharmaceutical marketplace; continue to seek opportunities to acquire companies, marketed or registration-stage products and late-stage development products that fit within the Company's focus areas; and generate revenues by marketing approved generic products through the Company's wholly-owned subsidiary, Aristos Pharmaceuticals, Inc. Chiesi USA, Inc. is a wholly-owned subsidiary of Chiesi Farmaceutici S.p.A. For more information, visit

PP-MULTI-005 V2.0

Contact Information